Abstracts tagged "ANA"

Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
David Pisetsky¹, Dana Thompson¹, Joseph Wajdula², Annette Diehl² and Sudhakar Sridharan³, ¹Duke University Medical Center and Durham VAMC, Durham, NC, ²Global Product Development, Pfizer Inc, Collegeville, PA, ³PPD Inc, Rockville, MD
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…
Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Luis E C Andrade¹, Jan Damoiseaux², Minoru Satoh³, Edward K.L. Chan⁴, Mônica Prado⁵, Henrique Mariz⁶, Renan Agustinelli⁷ and Alessandra Dellavance⁸, ¹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Dept of Oral Biology, University of Florida, Gainesville, FL, ⁵Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ⁷Rheumatology Division, Escola Paulista de Medicina, São Paulo, Brazil, ⁸Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…
Abstract Number: 1346 • 2016 ACR/ARHP Annual Meeting
Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease
Diana P. Pena¹ and Anca D. Askanase², ¹Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, ²Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: To compare clinical and immunological characteristics in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxycholoroquine (HCQ) in a large academic clinical practice.…
Abstract Number: 1769 • 2016 ACR/ARHP Annual Meeting
Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Rawad Nori¹, Babak Noamani², Dennisse Bonilla², Larissa Lisnevskaia³, Earl Silverman⁴, Arthur Bookman⁵, Sindhu R. Johnson¹, Carolina Landolt-Marticorena² and Joan Wither², ¹Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Lakeridge Health Services, Oshawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Fatigue is a common symptom of Systemic Autoimmune Rheumatic Disease (SARD) and has been proposed to result from the elaboration of pro-inflammatory factors in…
Abstract Number: 1874 • 2016 ACR/ARHP Annual Meeting
Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests
Louise Parker¹, Kevin Howell², Voon H. Ong³ and Christopher P.Denton⁴, ¹Centre for Rheumatology and Connective Diseases, UCL Medical School and Royal Free Hosp, London, United Kingdom, ²Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, ³Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Raynaud’s phenomenon is common but can progress to definite connective tissue disease. We have observed long term follow up of an unselected consecutive…
Abstract Number: 2147 • 2016 ACR/ARHP Annual Meeting
Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease
Waleed Hafiz¹, Nan-Hua Chang², Babak Noamani³, Dennisse Bonilla³, Larissa Lisnevskaia⁴, Earl Silverman⁵, Arthur Bookman⁶, Sindhu R. Johnson⁷, Carolina Landolt-Marticorena³ and Joan Wither³, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Lakeridge Health Services, Oshawa, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Rheumatology, University Health Network, Toronto, ON, Canada, ⁷Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: Patients with Systemic Autoimmune Rheumatic Disease (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA) positive but lack clinical…
Abstract Number: 2809 • 2016 ACR/ARHP Annual Meeting
Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories
Marc Chevrier, Jarrat Jordan, Jessica Schreiter and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: Serological positivity defined by presence of anti-nuclear antibodies (ANA) is frequently used in interventional lupus trials as an inclusion criterion and longitudinal biomarker. As such,…
Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Mônica Simon Prado¹, Alessandra Dellavance², Sílvia H. Rodrigues³ and Luis Eduardo C. Andrade^4,5, ¹Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, São Paulo, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁴Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁵Fleury Health and Medicine, Sao Paulo, Brazil
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…
Abstract Number: 2918 • 2016 ACR/ARHP Annual Meeting
The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Ashraf Raslan¹, Clifford Stermer² and Vivien Hsu³, ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Medicine, Rutgers-RWJMS, New York, NY, ³Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Antinuclear antibody (ANA) test is positive in nearly 95% of patients with systemic sclerosis (SSc) [1]. We aim to identify the clinical relevance of…
Abstract Number: 2482 • 2015 ACR/ARHP Annual Meeting
Choosing Subserologies More Wisely: Implementing Anti-Nuclear Antibody (ANA) Reflex Testing and Education to Reduce Unnecessary Costs in an Integrated Healthcare System
David Bulbin¹, Alicia Meadows², Sandi Kelsey³, Andrea Berger⁴, H. Lester Kirchner⁴, Harold Harrison³ and Alfred E. Denio⁵, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Rheumatology, Geisinger Health System, Danville, PA, ³Dept of Pathology, Geisinger Medical Center, Danville, PA, ⁴Biostatistics, Geisinger Center for Health Research, Danville, PA, ⁵Dept of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: The American College of Rheumatology published its Top 5 List of Things Physicians and Patients Should Question as part of the American Board…
Abstract Number: 2936 • 2015 ACR/ARHP Annual Meeting
Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Murray Urowitz^1,2, Dafna Gladman¹, Nicole Anderson³, Jiandong Su¹ and Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The evolution on an annual basis of disease activity and damage and the annual accrual of ACR criteria and key autoantibodies in patients with…
Abstract Number: 197 • 2015 ACR/ARHP Annual Meeting
Synergy Between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of Dnase II Deficient Mice
Rebecca Baum¹, Kerstin Nundel¹, Sudesh Pawaria^1,2, Shruti Sharma¹, Patricia Busto¹, Tara Robidoux¹, Katherine A. Fitzgerald¹, Ellen M. Gravallese³ and Ann Marshak-Rothstein¹, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Toll-like receptors (TLRs) dependent on Unc93b1 and cytosolic sensors dependent on STING detect microbial and endogenous nucleic acids to initiate inflammatory responses that resolve…
Abstract Number: 273 • 2015 ACR/ARHP Annual Meeting
Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study
Maria Garcia-Gonzalez, Esmeralda Delgado-Frias, Sagrario Bustabad, Ivan Ferraz-Amaro and Beatriz Rodriguez-Lozano, Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: In recent years there has been a growing interest in establishing the concept of Undifferentiated CTD (UCTD) and defining its clinical evolution. Remarkable are…
Abstract Number: 564 • 2015 ACR/ARHP Annual Meeting
Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis
Corina Mogosan¹, Luminita Enache¹, Denisa Stanciu¹, Daniela Opris², Simona Rednic³, Magda Parvu⁴, Horatiu Popoviciu⁵, Ruxandra Ionescu² and Catalin Codreanu¹, ¹Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ³Rheumatology, Emergency County Clinical Hospital Cluj Napoca, Cluj-Napoca, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rheumatology, Emergency County Hospital, Targu Mures, Romania
Background/Purpose: Therapeutic target in rheumatoid arthritis (RA) aims at achieving remission or low disease activity. Among the known poor prognostic factors are anti–citrullinated protein antibody…
Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
May Choi¹, John G. Hanly², Murray Urowitz^3,4, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Daniel J Wallace⁹, Joan T. Merrill¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Ellen M. Ginzler¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian N. Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Kristján Steinsson²³, Ola Nived²⁴, Gunnar K. Sturfelt²⁵, Susan Manzi²⁶, Munther Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Guillermo Ruiz-Irastorza³⁰, S. Sam Lim³¹, Thomas Stoll³², Murat Inanc³³, Kenneth C. Kalunian³⁴, Diane L. Kamen³⁵, Peter Maddison³⁶, Christine A. Peschken³⁷, Søren Jacobsen³⁸, Anca Askanase³⁹, Jill P. Buyon⁴⁰, W. Winn Chatham⁴¹, Manuel Ramos-Casals⁴², Yvan St. Pierre⁴³, Ann E. Clarke⁴⁴ and Marvin J. Fritzler¹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Rheumatology, TWH, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁷Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁹Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹²Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹³Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁴Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ¹⁹UNC Kidney Centre, Chapel Hill, NC, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁵Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁶Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁷Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²⁹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁵Medicine, Medical University of South Carolina, Charleston, SC, ³⁶School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³⁷Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ³⁸Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁹Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁰Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴¹Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴²Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴⁴Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.